Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-22
2005-03-22
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000
Reexamination Certificate
active
06869958
ABSTRACT:
This invention provides compounds defined by Formula Ior a pharmaceutically acceptable salt thereof,wherein R1, Q, Y1, Y2, Y3, and R2are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.
REFERENCES:
patent: 6008243 (1999-12-01), Bender et al.
patent: 6414157 (2002-07-01), Lubisch et al.
patent: 6656932 (2003-12-01), Picard et al.
patent: 20020151555 (2002-10-01), Barvian et al.
patent: 20020151558 (2002-10-01), Andrianjara et al.
patent: 20020156061 (2002-10-01), Barvian et al.
patent: 20020156069 (2002-10-01), Picard et al.
patent: 20020161000 (2002-10-01), Barvian et al.
patent: 20020193377 (2002-12-01), Andrianjara et al.
patent: 20030004172 (2003-01-01), Harter et al.
patent: 20030078276 (2003-04-01), Andrianjara, et al.
patent: 20030087924 (2003-05-01), Sorenson
patent: 20030130278 (2003-07-01), Gaudilliere et al.
patent: 20030144274 (2003-07-01), Bunker et al.
patent: 20030216402 (2003-11-01), Gaudilliere et al.
patent: 20030220355 (2003-11-01), Gaudilliere et al.
patent: 20040006077 (2004-01-01), Gaudilliere et al.
patent: 0 935 963 (1999-08-01), None
patent: 0 935 963 (1999-08-01), None
patent: 1 138 680 (2001-10-01), None
patent: WO 0009485 (2000-02-01), None
patent: WO 0112611 (2001-02-01), None
patent: WO 0163244 (2001-08-01), None
patent: WO 0234726 (2002-05-01), None
patent: WO 0234726 (2002-05-01), None
patent: WO 0234753 (2002-05-01), None
patent: WO 0234753 (2002-05-01), None
patent: WO 02064080 (2002-08-01), None
patent: WO 02064080 (2002-08-01), None
patent: WO 02064547 (2002-08-01), None
patent: WO 02064547 (2002-08-01), None
patent: WO 02064568 (2002-08-01), None
patent: WO 02064571 (2002-08-01), None
patent: WO 02064572 (2002-08-01), None
patent: WO 02064578 (2002-08-01), None
patent: WO 02064595 (2002-08-01), None
patent: WO 02064598 (2002-08-01), None
patent: WO 02064599 (2002-08-01), None
patent: WO 03032999 (2003-04-01), None
patent: WO 03033477 (2003-04-01), None
patent: WO 03033478 (2003-04-01), None
patent: WO 03076417 (2003-09-01), None
patent: WO 03076417 (2003-09-01), None
patent: WO 04000322 (2003-12-01), None
International Search Report for PCT International Application No. PCT/IB03/03662.
U.S. patent application Ser. No. 10/071,032, Dyer et al., filed Feb. 8, 2002.
U.S. patent application Ser. No. 10/634,531, Johnson, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,709, Bunker et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,162, Wilson, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,473, Bunker et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,289, Bunker et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,180, Bunker et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,712, Hicks et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,489, Roark, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,420, Roark, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,716, Nahra et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,288, O'Brien, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,717, Nahra et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,177, Wilson, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,290, Wilson, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,182, Li, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,419, Hicks et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,713, Picard, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,225, Picard et al., filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/634,718, Ortwine, filed Aug. 5, 2003.
U.S. patent application Ser. No. 10/739,261, Bunker et al., filed Dec. 18, 2003.
Office Action from 10/264,764 (PC20536A) mailed Jun. 16, 2003.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000, vol. 122, pp. 9648-9654.
Lovejoy et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biology, 1999, vol. 6, No. 3, pp. 217-221.
Moy et al., “High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor”, J. Mol. Biol., 2000, vol. 302, 671-689.
Mitchell et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin, Invest., 1996, vol. 97, No. 3, pp. 761-768.
Neuhold et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) reduces osteoarthritis in mice”, J. Clin. Invest., 2001, vol. 107, No. 1, pp. 35-44.
Dahlberg et al., “Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritis Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase 1 (Matrix Metalloproteinase 1)”, Arthrit. & Rheum., 2000, vol. 43, No. 3, pp. 673-682.
Billinghurst et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selection Inhibition of Type II Collagen Cleavage by Collagenase”, Arthrit. & Rheum., 2000, vol. 43, No. 3, pp. 664-672.
Billinghurst et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997, vol. 99, No. 7, pp. 1534-1545.
Hirota et al., “Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative Coupling”, Heterocycles, 1994, vol. 37, No. 1, pp. 563-570.
Ashbrook Charles W.
Aulakh Charanjit S.
Pfizer Inc.
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Fused tetrahydropyridine derivatives as matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused tetrahydropyridine derivatives as matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused tetrahydropyridine derivatives as matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409396